Nxera Pharma (SOLTF) Short Interest Ratio & Short Volume $7.75 +0.50 (+6.90%) (As of 11/4/2024 ET) Add Compare Share Share Short Interest Stock AnalysisChartHeadlinesShort Interest Nxera Pharma Short Interest DataNxera Pharma (SOLTF) has a short interest of 2.02 million shares. This marks a 6.95% increase in short interest from the previous month. The short interest ratio (days to cover) is 20,186.0, indicating that it would take 20,186.0 days of the average trading volume of 1,488 shares to cover all short positions.Current Short Interest2,018,600 sharesPrevious Short Interest1,887,500 sharesChange Vs. Previous Month+6.95%Dollar Volume Sold Short$18.21 millionShort Interest Ratio20,186.0 Days to CoverLast Record DateOctober 15, 2024Today's Trading Volume110 sharesAverage Trading Volume1,488 sharesToday's Volume Vs. Average7% Short Selling Nxera Pharma? Sign up to receive the latest short interest report for Nxera Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSOLTF Short Interest Over TimeSOLTF Days to Cover Over TimeSOLTF Percentage of Float Shorted Over Time Ad WealthPressCould TSLA reach $500 a share? Free ebook says it’s possible.Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future.To claim your copy, follow this link Nxera Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/15/20242,018,600 shares $18.21 million +7.0%N/A20186 $9.02 9/30/20241,887,500 shares $17.27 million -5.9%N/A18875 $9.15 9/15/20242,006,700 shares $16.50 million -16.6%N/A20067 $8.22 8/31/20242,405,300 shares $22.73 million +2.0%N/A24053 $9.45 8/15/20242,359,000 shares $22.32 million +3.5%N/A23590 $9.46 7/31/20242,278,700 shares $24.00 million -7.0%N/A22787 $10.53 Get the Latest News and Ratings for SOLTF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Nxera Pharma and its competitors with MarketBeat's FREE daily newsletter. 7/15/20242,450,700 shares $25.09 million +3.4%N/A24507 $10.24 6/30/20242,370,400 shares $22.35 million +0.2%N/A23704 $9.43 6/15/20242,365,000 shares $23.65 million +7.5%N/A11824.9 $10.00 5/31/20242,200,500 shares $19.52 million -9.1%N/A7335 $8.87 5/15/20242,419,800 shares $23.71 million -1.6%N/A12099 $9.80 4/30/20242,460,000 shares $22.89 million +13.1%N/A8200 $9.30 4/15/20242,175,400 shares $22.71 million +8.9%N/A7251.3 $10.44 3/31/20241,996,800 shares $21.02 million -7.4%N/A19968 $10.53 3/15/20242,156,300 shares $23.17 million -5.0%N/A287.5 $10.75 2/29/20242,269,300 shares $19.79 million +13.2%N/A22693 $8.72 2/15/20242,004,900 shares $17.34 million +22.3%N/A5012.3 $8.65 1/15/20241,294,200 shares $14.09 million -1.2%N/A2157 $10.89 12/31/20231,309,700 shares $13.10 million +8.2%N/A1437.6 $10.00 12/15/20231,211,000 shares $12.09 million -9.0%N/A2422 $9.98 11/30/20231,330,900 shares $13.24 million +25.3%N/A3327.3 $9.95 11/15/20231,062,100 shares $10.38 million -29.0%N/A5310.5 $9.77 10/31/20231,495,200 shares $13.35 million -6.8%N/A4984 $8.93 10/15/20231,603,600 shares $15.91 million -1.7%N/A1781.8 $9.92 9/30/20231,631,100 shares $16.64 million -6.0%N/A1812.3 $10.20 9/15/20231,735,300 shares $18.48 million -0.5%N/A2169.1 $10.65 8/31/20231,743,600 shares $20.26 million -0.8%N/A1748.9 $11.62 8/15/20231,757,400 shares $21.09 million -17.2%N/A5858 $12.00 7/31/20232,121,800 shares $27.48 million +52.4%N/A5304.5 $12.95 7/15/20231,392,500 shares $15.08 million +8.6%N/A633 $10.83 6/30/20231,281,900 shares $13.46 million -15.3%N/A145.7 $10.50 6/15/20231,513,300 shares $32.28 million -31.4%N/A1513.3 $21.33 5/31/20232,204,300 shares $49.37 million +6.7%N/A4408.6 $22.40 5/15/20232,065,500 shares $43.54 million +13.8%N/A10327.5 $21.08 4/30/20231,815,800 shares $35.92 million +19.7%N/A1513.2 $19.78 4/15/20231,516,400 shares $30.72 million +13.3%N/A3791 $20.26 3/31/20231,338,100 shares $22.68 million +3.1%N/A418.2 $16.95 3/15/20231,297,400 shares $23.56 million +19.7%N/A158.2 $18.16 2/28/20231,083,900 shares $17.61 million +1.3%N/A142.6 $16.25 2/15/20231,069,700 shares $16.63 million -5.1%N/A10697 $15.54This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here 1/31/20231,127,500 shares $17.53 million +14.3%N/A0 $15.54 1/15/2023986,700 shares $15.34 million +27.9%N/A4933.5 $15.54 12/30/2022771,500 shares $11.99 million +1.2%N/A7715 $15.54 12/15/2022762,600 shares $8.66 million -14.9%N/A0 $11.36 11/30/2022896,200 shares $10.18 million -18.0%N/A0 $11.36 11/15/20221,093,100 shares $12.42 million -7.4%N/A0 $11.36 10/31/20221,180,100 shares $13.41 million -9.7%N/A0 $11.36 10/15/20221,306,300 shares $14.84 million -3.8%N/A0 $11.36 9/30/20221,357,200 shares $15.42 million +0.8%N/A0 $11.36 9/15/20221,346,500 shares $15.30 million -3.7%N/A0 $11.36 8/31/20221,397,800 shares $15.88 million +32.3%N/A6989 $11.36 8/15/20221,056,200 shares $13.04 million +5.9%N/A3520.7 $12.35 7/31/2022997,700 shares $8.42 million -2.6%N/A0 $8.44 7/15/20221,024,600 shares $8.65 million -24.0%N/A0 $8.44 6/30/20221,347,300 shares $11.37 million -1.9%N/A0 $8.44 6/15/20221,373,200 shares $11.59 million -7.6%N/A0 $8.44 5/31/20221,485,500 shares $12.54 million -1.9%N/A0 $8.44 5/15/20221,514,900 shares $12.79 million -0.5%N/A15149 $8.44 4/30/20221,521,700 shares $19.60 million -3.5%N/A0 $12.88 4/15/20221,577,200 shares $20.31 million +0.9%N/A0 $12.88 3/31/20221,563,500 shares $20.14 million +7.6%N/A0 $12.88 3/15/20221,453,100 shares $18.72 million -3.3%N/A14531 $12.88 2/28/20221,502,400 shares $19.19 million -23.8%N/A0 $12.77 2/15/20221,970,800 shares $25.17 million -10.2%N/A0 $12.77 1/31/20222,193,500 shares $28.01 million -12.0%N/A10967.5 $12.77 1/15/20222,491,300 shares $42.53 million +9.2%N/A0 $17.07 12/31/20212,280,600 shares $38.93 million +6.2%N/A22806 $17.07 12/15/20212,148,000 shares $40.00 million +2.3%N/A0 $18.62 11/30/20212,100,300 shares $44.13 million +35.8%N/A21003 $21.01 11/15/20211,546,400 shares $23.86 million +1.5%N/A7732 $15.43 10/29/20211,523,900 shares $26.94 million -0.3%N/A0 $17.68 10/15/20211,529,100 shares $27.03 million +12.6%N/A0 $17.68 9/30/20211,358,400 shares $24.65 million -7.5%N/A13584 $18.15 9/15/20211,467,700 shares $23.97 million +0.5%N/A0 $16.33 8/31/20211,459,800 shares $23.84 million +3.2%N/A0 $16.33 8/13/20211,414,500 shares $23.10 million -2.0%N/A0 $16.33 7/30/20211,443,400 shares $23.57 million -0.1%N/A0 $16.33 7/15/20211,444,200 shares $23.58 million +22.3%N/A7221 $16.33 6/30/20211,180,500 shares $19.28 million +8.7%N/A11805 $16.33 6/15/20211,085,800 shares $14.40 million +13.5%N/A0 $13.26 5/28/2021956,600 shares $12.68 million +1.4%N/A1594.3 $13.26 5/14/2021943,100 shares $15.61 million +2.2%N/A0 $16.55 4/30/2021922,600 shares $15.27 million -0.3%N/A0 $16.55 4/15/2021925,400 shares $15.32 million -11.0%N/A0 $16.55 3/31/20211,039,500 shares $17.20 million -10.2%N/A0 $16.55 3/15/20211,157,500 shares $19.16 million -22.9%N/A11575 $16.55 2/26/20211,500,700 shares $24.45 million -17.1%N/A0 $16.29 2/12/20211,810,000 shares $29.48 million -7.4%N/A0 $16.29 1/29/20211,954,800 shares $31.84 million +9.6%N/A0 $16.29 1/15/20211,605,500 shares $26.15 million -6.0%N/A16055 $16.29The Final Frontier (Ad)And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. 12/31/20201,712,600 shares $27.04 million +6.7%N/A0 $15.79 12/15/20201,605,500 shares $25.35 million -6.0%N/A16055 $15.79 11/30/20201,708,300 shares $25.45 million +17.1%N/A0 $14.90 11/15/20201,458,900 shares $20.05 million -6.4%N/A14589 $13.74 10/30/20201,557,900 shares $17.39 million +12.0%N/A7789.5 $11.16 10/15/20201,391,000 shares $17.62 million +3.0%N/A0 $12.67 9/30/20201,351,200 shares $17.12 million +5.0%N/A6756 $12.67 9/15/20201,287,400 shares $17.23 million +7.0%N/A1839.1 $13.38 8/31/20201,202,800 shares $16.48 million +18.8%N/A0 $13.70 8/14/20201,012,700 shares $13.87 million -4.2%N/A10127 $13.70 7/31/20201,056,500 shares $15.27 million +0.7%N/A1760.8 $14.45 7/15/20201,048,800 shares $16.79 million +48.3%N/A0 $16.01 6/30/2020707,400 shares $11.33 million -1.9%N/A3537 $16.01 6/15/2020721,100 shares $10.43 million +2.4%N/A7211 $14.47 5/29/2020704,500 shares $8.45 million +1.3%N/A0 $12.00 5/15/2020695,600 shares $8.35 million -12.4%N/A0 $12.00 4/30/2020794,400 shares $9.53 million -5.3%N/A0 $12.00 4/15/2020838,700 shares $10.06 million -12.1%N/A8387 $12.00 3/31/2020953,600 shares $11.44 million -11.9%N/A0 $12.00 3/13/20201,082,400 shares $12.99 million -1.4%N/A10824 $12.00 2/28/20201,097,900 shares $14.33 million +3.3%N/A0 $13.05 2/14/20201,062,500 shares $13.87 million +2.6%N/A0 $13.05 1/31/20201,035,200 shares $17.92 million -4.5%N/A0 $17.31 1/15/20201,084,000 shares $20.30 million -10.3%N/A10840 $18.73 12/31/20191,208,100 shares $22.63 million +14.2%N/A12081 $18.73 SOLTF Short Interest - Frequently Asked Questions What is Nxera Pharma's current short interest? Short interest is the volume of Nxera Pharma shares that have been sold short but have not yet been covered or closed out. As of October 15th, investors have sold 2,018,600 shares of SOLTF short. Learn More on Nxera Pharma's current short interest. What is a good short interest ratio for Nxera Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SOLTF shares currently have a short interest ratio of 20,186.0. Learn More on Nxera Pharma's short interest ratio. Is Nxera Pharma's short interest increasing or decreasing? Nxera Pharma saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 2,018,600 shares, an increase of 6.9% from the previous total of 1,887,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.14 billion), AppLovin Co. ($3.15 billion), Paychex, Inc. ($2.69 billion), Nu Holdings Ltd. ($2.48 billion), Cencora, Inc. ($2.24 billion), International Paper ($2.04 billion), Tractor Supply ($1.96 billion), Coinbase Global, Inc. ($1.93 billion), Moderna, Inc. ($1.91 billion), and SoFi Technologies, Inc. ($1.84 billion). View all of the most shorted stocks. What does it mean to sell short Nxera Pharma stock? Short selling SOLTF is an investing strategy that aims to generate trading profit from Nxera Pharma as its price is falling. SOLTF shares are trading up $0.50 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Nxera Pharma? A short squeeze for Nxera Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SOLTF, which in turn drives the price of the stock up even further. How often is Nxera Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SOLTF, twice per month. The most recent reporting period available is October, 15 2024. More Short Interest Resources from MarketBeat Related Companies ATNFW Short Interest Data TRSBF Short Interest Data AGNPF Short Interest Data DRTSW Short Interest Data WENAW Short Interest Data APLMW Short Interest Data ASPHF Short Interest Data ASCLF Short Interest Data AVCTF Short Interest Data AWKNF Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:SOLTF) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredNASDAQ small cap that could be gearing up for a massive short squeeze.A Heavy Short Interest Could Lead to a Monstrous Short Squeeze for this Tiny NASDAQ Healthcare Firm!Huge Alerts | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nxera Pharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nxera Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SOLTF Stock Alerts